Value-Based Contracting: CMS Final Rule Leaves ‘Multiple Best Price’ Questions Unresolved
Implementation of ‘multiple best price’ reporting approach to facilitate value-based payment arrangements postponed until 2022 to allow time for further guidance to be developed, but new definition of VBP arrangements is effective in March.
You may also be interested in...
Outcomes and disease progression could be clear cut, lending the rare disease treatment to innovative contracting. But the amount of money at stake is likely to complicate things.
Pfizer's Xalkori warranty program uses a third party to provide any refunds approved, which would exempt them from best price reporting requirements.
A bluebird executive spoke during ARM’s Cell and Gene Meeting On The Mesa about why the firm pulled Zynteglo out of the EU, but while progress has been made in the US, long-term challenges remain.